妇科癌症患者肠外注射羧甲基麦芽糖酸铁的临床和经济效益:回顾性观察研究

Q4 Medicine
V. Saevets, A. Shamanova
{"title":"妇科癌症患者肠外注射羧甲基麦芽糖酸铁的临床和经济效益:回顾性观察研究","authors":"V. Saevets, A. Shamanova","doi":"10.26442/18151434.2023.3.202442","DOIUrl":null,"url":null,"abstract":"Background. Timely diagnosis and treatment of iron deficiency anemia in cancer patients affect the quality of life and the effectiveness of anti-tumor treatment. However, choosing a method for correcting anemia is imperative to achieve maximum efficiency and safety with the least financial costs. \nAim. To evaluate postoperative methods for treating iron deficiency anemia in patients with gynecological cancers based on a comparative analysis of the clinical and economic outcomes of intravenous iron carboxymaltosate and blood transfusions. \nMaterials and methods. A study of 125 cases of malignant neoplasms of the female reproductive system with a history of iron deficiency anemia was conducted. Study Group 1 included 85 patients with malignancies receiving 500–1000 mg of iron carboxymaltosate (ICM) intravenously; Group 2 included 40 patients with transfusion of packed red cells (PRC). Clinical and economic outcomes of methods for anemia treatment were analyzed. \nResults. In Group 1, the maximum increase in hemoglobin level was observed from Week 2 of ICM treatment (median increase 1.3 g/dL) peaking by Week 9–10 (median increase 2.3 g/dL). In Group 2 the maximum increase in hemoglobin level was noted at Week 1 after PRC transfusion (median increase 2.1 g/dL), with a gradually decreasing hemoglobin level for 3 weeks after that. No side effects of ICM treatment were reported. In 7 (17.5%) patients, a pyrogenic reaction (hyperthermia) was reported after a blood transfusion. The median time from surgery to the beginning of anti-tumor treatment (radiation therapy, chemotherapy) in Group 1 was 19 days [17; 25] vs. 26 days [22; 30] in Group 2 (p=0.0021). \nConclusion. High-dose ICM therapy for iron deficiency anemia in patients with gynecological malignancies is cost-effective and shows a long-term clinical effect.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"1117 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and economic benefits of parenteral iron carboxymaltosate in patients with gynecological cancers: A retrospective observational study\",\"authors\":\"V. Saevets, A. Shamanova\",\"doi\":\"10.26442/18151434.2023.3.202442\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background. Timely diagnosis and treatment of iron deficiency anemia in cancer patients affect the quality of life and the effectiveness of anti-tumor treatment. However, choosing a method for correcting anemia is imperative to achieve maximum efficiency and safety with the least financial costs. \\nAim. To evaluate postoperative methods for treating iron deficiency anemia in patients with gynecological cancers based on a comparative analysis of the clinical and economic outcomes of intravenous iron carboxymaltosate and blood transfusions. \\nMaterials and methods. A study of 125 cases of malignant neoplasms of the female reproductive system with a history of iron deficiency anemia was conducted. Study Group 1 included 85 patients with malignancies receiving 500–1000 mg of iron carboxymaltosate (ICM) intravenously; Group 2 included 40 patients with transfusion of packed red cells (PRC). Clinical and economic outcomes of methods for anemia treatment were analyzed. \\nResults. In Group 1, the maximum increase in hemoglobin level was observed from Week 2 of ICM treatment (median increase 1.3 g/dL) peaking by Week 9–10 (median increase 2.3 g/dL). In Group 2 the maximum increase in hemoglobin level was noted at Week 1 after PRC transfusion (median increase 2.1 g/dL), with a gradually decreasing hemoglobin level for 3 weeks after that. No side effects of ICM treatment were reported. In 7 (17.5%) patients, a pyrogenic reaction (hyperthermia) was reported after a blood transfusion. The median time from surgery to the beginning of anti-tumor treatment (radiation therapy, chemotherapy) in Group 1 was 19 days [17; 25] vs. 26 days [22; 30] in Group 2 (p=0.0021). \\nConclusion. High-dose ICM therapy for iron deficiency anemia in patients with gynecological malignancies is cost-effective and shows a long-term clinical effect.\",\"PeriodicalId\":16401,\"journal\":{\"name\":\"Journal of Modern Oncology\",\"volume\":\"1117 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Modern Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.26442/18151434.2023.3.202442\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Modern Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/18151434.2023.3.202442","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景。及时诊断和治疗癌症患者的缺铁性贫血会影响其生活质量和抗肿瘤治疗的效果。然而,要以最少的经济成本实现最高的效率和安全性,选择一种纠正贫血的方法势在必行。目的是通过比较分析静脉注射羧甲基铁和输血的临床和经济效果,评估治疗妇科癌症患者术后缺铁性贫血的方法。材料和方法。对 125 例有缺铁性贫血病史的女性生殖系统恶性肿瘤患者进行了研究。研究组 1 包括 85 名恶性肿瘤患者,他们接受了 500-1000 毫克羧甲基麦芽糖酸铁(ICM)静脉注射;研究组 2 包括 40 名患者,他们接受了包装红细胞(PRC)输血。对贫血治疗方法的临床和经济效果进行了分析。结果显示在第 1 组中,血红蛋白水平从 ICM 治疗的第 2 周开始出现最大增幅(中位数增幅为 1.3 克/分升),到第 9-10 周达到峰值(中位数增幅为 2.3 克/分升)。第 2 组的血红蛋白水平在输注 PRC 后的第 1 周达到最高值(中位数为 2.1 克/分升),此后 3 周血红蛋白水平逐渐下降。没有关于 ICM 治疗副作用的报告。有 7 例(17.5%)患者在输血后出现热原反应(高热)。第一组患者从手术到开始抗肿瘤治疗(放疗、化疗)的中位时间为 19 天 [17; 25] ,第二组为 26 天 [22; 30] (P=0.0021)。结论大剂量 ICM 治疗妇科恶性肿瘤患者的缺铁性贫血具有成本效益,并显示出长期临床效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical and economic benefits of parenteral iron carboxymaltosate in patients with gynecological cancers: A retrospective observational study
Background. Timely diagnosis and treatment of iron deficiency anemia in cancer patients affect the quality of life and the effectiveness of anti-tumor treatment. However, choosing a method for correcting anemia is imperative to achieve maximum efficiency and safety with the least financial costs. Aim. To evaluate postoperative methods for treating iron deficiency anemia in patients with gynecological cancers based on a comparative analysis of the clinical and economic outcomes of intravenous iron carboxymaltosate and blood transfusions. Materials and methods. A study of 125 cases of malignant neoplasms of the female reproductive system with a history of iron deficiency anemia was conducted. Study Group 1 included 85 patients with malignancies receiving 500–1000 mg of iron carboxymaltosate (ICM) intravenously; Group 2 included 40 patients with transfusion of packed red cells (PRC). Clinical and economic outcomes of methods for anemia treatment were analyzed. Results. In Group 1, the maximum increase in hemoglobin level was observed from Week 2 of ICM treatment (median increase 1.3 g/dL) peaking by Week 9–10 (median increase 2.3 g/dL). In Group 2 the maximum increase in hemoglobin level was noted at Week 1 after PRC transfusion (median increase 2.1 g/dL), with a gradually decreasing hemoglobin level for 3 weeks after that. No side effects of ICM treatment were reported. In 7 (17.5%) patients, a pyrogenic reaction (hyperthermia) was reported after a blood transfusion. The median time from surgery to the beginning of anti-tumor treatment (radiation therapy, chemotherapy) in Group 1 was 19 days [17; 25] vs. 26 days [22; 30] in Group 2 (p=0.0021). Conclusion. High-dose ICM therapy for iron deficiency anemia in patients with gynecological malignancies is cost-effective and shows a long-term clinical effect.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Modern Oncology
Journal of Modern Oncology Medicine-Oncology
CiteScore
0.50
自引率
0.00%
发文量
0
审稿时长
5 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信